NCT04938232View on ClinicalTrials.gov

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 4, 2021

Primary Completion Date

April 1, 2024

Study Completion Date

August 1, 2026

Conditions
Hodgkin LymphomaRelapsed Hodgkin's Disease, AdultRefractory Hodgkin Lymphoma
Interventions
DRUG

Nivolumab

Intravenous infusion

DRUG

Ipilimumab

Intravenous infusion

Trial Locations (4)

60637

University of Chicago Medicine, Chicago

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT04938232 - Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | Biotech Hunter | Biotech Hunter